<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02678299</url>
  </required_header>
  <id_info>
    <org_study_id>PREBEN</org_study_id>
    <secondary_id>2015-000758-39</secondary_id>
    <nct_id>NCT02678299</nct_id>
  </id_info>
  <brief_title>Phase 1/2 Study of the Combination of Pixantrone, Etoposide, Bendamustine and, in CD20 Positive Tumors, Rituximab in Patients With Relapsed Aggressive Non-Hodgkin Lymphomas of B- or T-cell Phenotype - the P[R]EBEN Study</brief_title>
  <official_title>Phase 1/2 Study of the Combination of Pixantrone, Etoposide, Bendamustine and, in CD20 Positive Tumors, Rituximab in Patients With Relapsed Aggressive Non-Hodgkin Lymphomas of B- or T-cell Phenotype - the P[R]EBEN Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Aarhus</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Aarhus</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a phase 1/2 open label study to assess the safety and efficacy of pixantrone in&#xD;
      combination with bendamustine, etoposide and , for CD20 positive B-cell lymphomas, rituximab&#xD;
      (P[R]EBEN), in patients with relapsed aNHL of B- or T-cell phenotype.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a phase 1/2 open label study to assess the safety and efficacy of pixantrone in&#xD;
      combination with bendamustine, etoposide and , for CD20 positive B-cell lymphomas, rituximab&#xD;
      (P[R]EBEN), in patients with relapsed aNHL of B- or T-cell phenotype.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>February 2016</start_date>
  <completion_date type="Anticipated">December 2025</completion_date>
  <primary_completion_date type="Anticipated">February 2022</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>MTD of pixantrone, bendamustine and etoposide in 'fit' relapsed aNHL pts (phase 1)</measure>
    <time_frame>1.5 yrs</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Objective ORR in both 'fit' and 'frail' relapsed aNHL pts (phase 2)</measure>
    <time_frame>4 yrs</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">60</enrollment>
  <condition>Malignant Lymphoma</condition>
  <arm_group>
    <arm_group_label>Treatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PREBEN</intervention_name>
    <arm_group_label>Treatment</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients with a histologically confirmed relapse of an aggressive lymphoma of T- or&#xD;
             B-cell phenotype (including follicular lymphoma grade 3b). For excluded histological&#xD;
             entities see 'Exclusion criteria'&#xD;
&#xD;
          -  Phase 1 + Phase 2 'fit' patients:&#xD;
&#xD;
               -  Age 18-70 years at the time of inclusion&#xD;
&#xD;
               -  ECOG PS 0-1 at protocol entry&#xD;
&#xD;
               -  Deemed 'fit' by the treating physician&#xD;
&#xD;
          -  Phase 2 'frail' patients:&#xD;
&#xD;
               -  Age 71-85 years at the time of inclusion and/or&#xD;
&#xD;
               -  ECOG PS 2-3 at protocol entry and/or&#xD;
&#xD;
               -  Deemed 'frail' by the treating physician&#xD;
&#xD;
          -  At least six months response duration since last given course of treatment&#xD;
&#xD;
          -  Estimated life expectancy of 3 months or longer&#xD;
&#xD;
          -  Measurable disease&#xD;
&#xD;
          -  Hemoglobin ≥ 8 g/dL (≥5 mmol/l)&#xD;
&#xD;
          -  Platelets ≥ 100 x 109/L; ≥ 75 x 109/L permitted if bone marrow involvement&#xD;
&#xD;
          -  Absolute neutrophil count ≥ 1.5 x 109/L; ≥ 1.0 x 109/L permitted if documented bone&#xD;
             marrow involvement&#xD;
&#xD;
          -  Serum bilirubin ≤ 1.5 x upper limit of normal (ULN); patients with proven Gilbert's&#xD;
             syndrome (≤ 5 x ULN) may be enrolled.&#xD;
&#xD;
          -  Serum glutamic-oxaloacetic transaminase (AST) and/or serum glutamic-pyruvic&#xD;
             transaminase (ALT) ≤ 2.5 x ULN, or ≤ 5 x ULN if elevation is due to hepatic&#xD;
             involvement by lymphoma&#xD;
&#xD;
          -  Serum creatinine ≤ 2 x ULNb&#xD;
&#xD;
          -  Women of childbearing potential must use safe anticonception (e.g. contraceptive&#xD;
             pills, intrauterine devices etc.) during the study and 12 months after the last&#xD;
             administration of study drugs&#xD;
&#xD;
          -  Male patients must use contraception for the duration of the study and 6 months after&#xD;
             the last administration of study drugs if his partner is of childbearing potential&#xD;
&#xD;
          -  Written informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients with primary refractory disease (e.g. progressing under platinum-containing&#xD;
             or similar salvage therapy) defined as &lt; 6 months response duration from last given&#xD;
             course of treatment.&#xD;
&#xD;
          -  High-dose therapy with autologous stem cell rescue within the last 6 months prior to&#xD;
             study entry.&#xD;
&#xD;
          -  Following T-cell lymphoma entities:&#xD;
&#xD;
               -  T-cell lymphoblastic lymphoma&#xD;
&#xD;
               -  Hepatosplenic T-cell lymphoma&#xD;
&#xD;
               -  Extranodal NK/T, nasal type&#xD;
&#xD;
               -  Subcutaneous panniculitis-like&#xD;
&#xD;
               -  Primary cutaneous T-cell lymphoma&#xD;
&#xD;
               -  Primary leukemic T-cell lymphoma&#xD;
&#xD;
          -  Following B-cell lymphoma entities:&#xD;
&#xD;
               -  Transformed indolent B-cell lymphomas&#xD;
&#xD;
               -  Post-transplant B-cell lymphoproliferative disease&#xD;
&#xD;
               -  HIV-associated B-cell lymphoma&#xD;
&#xD;
          -  Concurrent severe and/or uncontrolled medical disease which is not lymphoma-related&#xD;
&#xD;
          -  Left ventricular ejection fraction (LVEF) &lt; 45%&#xD;
&#xD;
          -  Suspected or documented central nervous system involvement by NHL&#xD;
&#xD;
          -  Patients known to be antigen positive for HIV and/or hepatitis B and/or hepatitis C&#xD;
&#xD;
          -  Patients with active, uncontrolled infections&#xD;
&#xD;
          -  Vaccination with live, attenuated vaccines within 4 weeks of inclusion&#xD;
&#xD;
          -  Pregnant and/or breastfeeding women&#xD;
&#xD;
          -  History of active cancer during the past 5 years, except basal carcinoma of the skin&#xD;
             or stage 0 cervical carcinoma&#xD;
&#xD;
          -  Known hypersensitivity to one or more of the study drugs&#xD;
&#xD;
          -  Unwillingness or inability to comply with the protocol&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Francesco d'Amore, MD DMSci</last_name>
    <role>Principal Investigator</role>
    <affiliation>Dept. of Hematology, Aarhus University Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Department of Hematology, Aarhus University Hospital</name>
      <address>
        <city>Aarhus</city>
        <zip>DK-8200</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Department of Hematology, Copenhagen University Hospital</name>
      <address>
        <city>Copenhagen</city>
        <zip>2100</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Department of Hematology, Odense University Hospital</name>
      <address>
        <city>Odense</city>
        <zip>5000</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Helsinki University Hospital Comprehensive Cancer Center</name>
      <address>
        <city>Helsinki</city>
        <zip>00029</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Meander Medical Center</name>
      <address>
        <city>Amersfoort</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Jeroen Bosch Hospital</name>
      <address>
        <city>Den Bosch</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Haga Hospital, loc. Leyweg</name>
      <address>
        <city>Den Haag</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Slingeland Hospital</name>
      <address>
        <city>Doetinchem</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Albert Schweitzer Hospital</name>
      <address>
        <city>Dordrecht</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medisch Spectrum Twente</name>
      <address>
        <city>Enschede</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitair Medisch Centrum Groningen</name>
      <address>
        <city>Groningen</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Spaarne Ziekenhuis</name>
      <address>
        <city>Hoofddorp</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Erasmus Medical Center</name>
      <address>
        <city>Rotterdam</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Admiraal de Ruyter Hospital</name>
      <address>
        <city>Vlissingen</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Department of Oncology, Oslo University Hospital</name>
      <address>
        <city>Oslo</city>
        <zip>0310</zip>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Stavanger University Hospital</name>
      <address>
        <city>Stavanger</city>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Department of Oncology, St. Olavs Hospital</name>
      <address>
        <city>Trondheim</city>
        <zip>7006</zip>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Department of Oncology, Skåne University Hospital</name>
      <address>
        <city>Lund</city>
        <zip>221 85</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Denmark</country>
    <country>Finland</country>
    <country>Netherlands</country>
    <country>Norway</country>
    <country>Sweden</country>
  </location_countries>
  <verification_date>April 2020</verification_date>
  <study_first_submitted>February 5, 2016</study_first_submitted>
  <study_first_submitted_qc>February 5, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 9, 2016</study_first_posted>
  <last_update_submitted>October 12, 2021</last_update_submitted>
  <last_update_submitted_qc>October 12, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 13, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Lymphoma, Non-Hodgkin</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

